Ankylosing spondylitis (Bechterew’s disease)

Disease description

Ankylosing spondylitis (also known as Bechterew’s disease) is a chronic inflammatory disorder that primarily affects the spinal joints and sacroiliac articulations. Over time, the condition can lead to the fusion of vertebrae, resulting in significantly reduced spinal mobility and severe pain. Statistically, the disease most commonly develops between the ages of 25 and 35.

Symptoms indicating the need for diagnosis and treatment:

• pain and stiffness in the lower back
• reduced spinal mobility
• increased thoracic kyphosis (curvature of the spine)
• pain in the hip, knee, or shoulder joints
• fatigue and general malaise

Diagnostic and treatment methods

Diagnosis

The diagnosis of ankylosing spondylitis includes a clinical examination, X-ray imaging, and magnetic resonance imaging (MRI). X-rays help detect early signs of inflammation and bony changes, such as vertebral fusion. MRI is used for a more detailed evaluation of soft tissues and to identify early inflammatory processes.

Treatment

The treatment of ankylosing spondylitis focuses on slowing the progression of the disease and improving the patient’s quality of life. The main treatment approaches include pharmacotherapy (nonsteroidal anti-inflammatory medications, biologic agents), physical therapy, and regular physical activity. In more advanced cases, surgical intervention may be required to correct spinal deformities or replace affected joints.

Innovations in global clinics

One of the major innovations in the treatment of ankylosing spondylitis is the use of biologic agents aimed at suppressing inflammatory mediators, such as tumor necrosis factor-alpha (TNF-α). These medications, known as TNF-α inhibitors, significantly slow disease progression by reducing inflammation and pain. When combined with a personalized approach to dosage and treatment monitoring, this therapy can dramatically improve patients’ quality of life.